



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 295/08, 295/22, C07C 233/41, A61K 31/535	A1	(11) International Publication Number ✓ WO 99/21846 (43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/US98/22765 (22) International Filing Date: 27 October 1998 (27.10.98) (30) Priority Data: 60/063,669 28 October 1997 (28.10.97) US (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL CORP. [US/US]; U.S. Route 202, Raritan, NJ 08869-0602 (US). (72) Inventors: CHEN, Robert, H.; 39 Beverly Drive, Belle Mead, NJ 08502 (US). XIANG, Min; 29 Forest Avenue, Bridgewater, NJ 08807 (US). MOORE, John, B., Jr.; 19 Goldfinch Lane, Neshanic Station, NJ 08853 (US). BEAVERS, Mary, Pat; 518 Waterford Court, New Hope, PA 18938 (US). (74) Agents: CIAMPORCERO, Audley et al.; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CYCLOPENTENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR		
(57) Abstract The compounds of formula (I) are useful in treating gastrointestinal disorders associated with antagonizing the motilin receptor disorders. The compounds compete with erythromycin and motilin for the motilin receptor. In addition the compounds are antagonists of the contractile smooth muscle response to those ligands.		